Apart from the GRPR- and PSMA- or GRPR- and integrin αvβ3-bispecific heterobivalent agents developed for PCa imaging or therapy, other strategies were followed to improve the targeting of this malignancy using peptide heterodimers. This evidence concerns the gene GRPR and posterior cortical atrophy.